{"id":1473,"date":"2020-06-01T21:05:32","date_gmt":"2020-06-01T21:05:32","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1473"},"modified":"2026-02-24T00:01:28","modified_gmt":"2026-02-24T00:01:28","slug":"a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/","title":{"rendered":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi)"},"content":{"rendered":"

BRCA2<\/em>, is a gene with a critical role in DNA repair and homologous recombination in somatic cells. Patients with biallelic alterations develop Fanconi Anemia (FA), a severe life-threatening condition \u00a0with pancytopenia and multiple malformations, while women with monoallelic alteration are at high risk to develop breast or ovarian cancer (up\u00a0to 60%). Here, we surprisingly uncovered a homozygous pathogenic variant of\u00a0BRCA2<\/em>\u00a0in a patient with isolated primary ovarian insufficiency but without cancer or FA in all her family. We demonstrated that this alteration only mildly altered the function of the protein and that BRCA2 is expressed in the fetal ovary in meiotic germinal cells undergoing a high level of DNA breaks and consequently repair. Our work extends the phenotype of\u00a0BRCA2<\/em> alteration to fully isolated POI. This has a major impact in the management and genetic counselling of patients and families. (https:\/\/jmg.bmj.com\/content\/early\/2020\/06\/01\/jmedgenet-2019-106672<\/a> )<\/p>\n","protected":false},"excerpt":{"rendered":"

BRCA2, is a gene with a critical role in DNA repair and homologous recombination in somatic cells. Patients with biallelic alterations develop Fanconi Anemia (FA), a severe life-threatening condition \u00a0with pancytopenia and multiple malformations, while women with monoallelic alteration are at high risk to develop breast or ovarian cancer (up\u00a0to 60%). Here, we surprisingly uncovered […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1473","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"\nA homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"BRCA2, is a gene with a critical role in DNA repair and homologous recombination in somatic cells. Patients with biallelic alterations develop Fanconi Anemia (FA), a severe life-threatening condition \u00a0with pancytopenia and multiple malformations, while women with monoallelic alteration are at high risk to develop breast or ovarian cancer (up\u00a0to 60%). Here, we surprisingly uncovered [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-01T21:05:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T00:01:28+00:00\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi)\",\"datePublished\":\"2020-06-01T21:05:32+00:00\",\"dateModified\":\"2026-02-24T00:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/\"},\"wordCount\":169,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/\",\"name\":\"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"datePublished\":\"2020-06-01T21:05:32+00:00\",\"dateModified\":\"2026-02-24T00:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2020\\\/06\\\/01\\\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/","og_locale":"en_US","og_type":"article","og_title":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog","og_description":"BRCA2, is a gene with a critical role in DNA repair and homologous recombination in somatic cells. Patients with biallelic alterations develop Fanconi Anemia (FA), a severe life-threatening condition \u00a0with pancytopenia and multiple malformations, while women with monoallelic alteration are at high risk to develop breast or ovarian cancer (up\u00a0to 60%). Here, we surprisingly uncovered [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/","og_site_name":"JMG Contact blog","article_published_time":"2020-06-01T21:05:32+00:00","article_modified_time":"2026-02-24T00:01:28+00:00","author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi)","datePublished":"2020-06-01T21:05:32+00:00","dateModified":"2026-02-24T00:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/"},"wordCount":169,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/","url":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/","name":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"datePublished":"2020-06-01T21:05:32+00:00","dateModified":"2026-02-24T00:01:28+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2020\/06\/01\/a-homozygous-hypomorphic-brca2-variant-in-primary-ovarian-insufficiency-without-cancer-or-fanconi-anemia-trait\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"A homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anemia trait (Contributed by Prof. Micheline Misrahi)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1473"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1473\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}